Another name that insiders find very attractive here is biotechnology and drugs player Amicus Therapeutics ( FOLD), which is focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. Insiders are sniffing out some value here, since the stock has dropped over 20% in the last six months. Amicus Therapeutics has a market cap of $230 million and an enterprise value of $124 million. This stock trades at a reasonable valuation, with a price-to-sales of 9.92 and a price-to-book of 2.85. Its estimated growth rate for this year is 15.6%, and for next year it's pegged at -5.6%. This is a cash-rich company, since the total cash position on its balance sheet is $108.20 million and its total debt is $1.73 million. >>4 Biotech Stocks Under $10 With Relative Strength A beneficial owner just bought 2,949,581 shares, or around $18.58 million worth of stock, at $6.30 per share. From a technical perspective, FOLD is currently trading below its 50-day moving average and just above its 200-day moving average, which is neutral trendwise. This stock has sold off hard over the last few trading sessions, with shares plunging from $6.89 to a recent low of $4.87 a share. That selloff has been accompanied with heavy selling volume, which is bearish technical action. That said, shares of FOLD have so far been defended right near its 200-day moving average of $4.77 a share. If you're in the bull camp on FOLD, I would look for long-biased trades if this stock can manage to hold a trend above its 200-day at $4.77 a share with strong upside volume flows. I would consider any upside volume day that registers near or above its three-month average action of 222,562 shares as bullish. If FOLD can manage to hold a trend above its 200-day, then I would look to add to any positions once it sustains a move or close back above its 50-day at $5.29 a share with heavy volume. If we get that action, then target a pop towards $6 or possibly a bit higher. On the flipside, I would avoid FOLD or look for short-biased trades if it fails to get back above its 50-day, and then takes out its 200-day at $4.77 a share with heavy volume. If we get that action, then FOLD will likely re-test its June low of $4.25 a share, or possibly even take that level out. Amicus shows up on a list of 22 Biopharma Stocks With Breakout Potential in 2012.